FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL							
	OMB Number:	3235-0287						
	Estimated average burden							
- 1	ha	٥٦						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

FAVORITO TAMARA A				3. E	2. Issuer Name and Ticker or Trading Symbol  ZEVRA THERAPEUTICS, INC. [ ZVRA ]  3. Date of Earliest Transaction (Month/Day/Year)					(Che	eck all applic	able)	Person(s) to Iss 10% Ov Other (s below)	vner	
(Last) (First) (Middle) C/O ZEVRA THERAPEUTICS, INC. 1180 CELEBRATION BOULEVARD, SUITE 103			4. 1	05/31/2023  4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
(Street) CELEBE	RATION FI		34747	D	مار	10hE 1	(0)	Trancac	tion Indi	oation		Form fi Person		than One Repo	rting
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
		Tak	ole I - Non-D	Derivative	e Se	curities	Acc	quired, Dis	sposed o	f, or Ber	eficiall	y Owned			
Date			Transaction ate lonth/Day/Ye	Execution Date,		3. Transaction Code (Instr. ) 8)  4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			Beneficia Owned F	es Formally (D) (Following (I) (I	orm: Direct	7. Nature of Indirect Beneficial Ownership			
						Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ion Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (I		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(5)	
Stock Option (right to buy)	\$5.04 <sup>(1)</sup>	05/31/2023		A		10,000 <sup>(2)</sup>		(3)	05/30/2033	Common Stock	10,000	\$0	10,000	D	

## **Explanation of Responses:**

- 1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 31, 2023.
- 2. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.
- 3. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Tamara A. 06/02/2023 Favorito

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.